Exenatide : effect of injection time on postprandial glucose in patients with Type 2 diabetesLINNEBJERG, H; KOTHARE, P. A; SKRIVANEK, Z et al.Diabetic medicine. 2006, Vol 23, Num 3, pp 240-245, issn 0742-3071, 6 p.Article

The effect of exenatide re-exposure on safety and efficacyFALUDI, Peter; BRODOWS, Robert; BURGER, Jude et al.Peptides (New York, NY. 1980). 2009, Vol 30, Num 9, pp 1771-1774, issn 0196-9781, 4 p.Article

Exenatide prevents high-glucose-induced damage of retinal ganglion cells through a mitochondrial mechanismMING HAO; KUANG, Hong-Yu; ZHENG FU et al.Neurochemistry international. 2012, Vol 61, Num 1, pp 1-6, issn 0197-0186, 6 p.Article

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in miceTREVASKIS, James L; GRIFFIN, Peter S; WITTMER, Carrie et al.American journal of physiology. Gastrointestinal and liver physiology. 2012, Vol 65, Num 4, issn 0193-1857, G762-G772Article

Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activityNIAN GONG; MA, Ai-Niu; ZHANG, Li-Jie et al.British journal of pharmacology. 2011, Vol 163, Num 2, pp 399-412, issn 0007-1188, 14 p.Article

A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4)CALARA, Federico; TAYLOR, Kristin; HAN, Jenny et al.Clinical therapeutics. 2005, Vol 27, Num 2, pp 210-215, issn 0149-2918, 6 p.Article

Exenatide : An incretin mimetic for the treatment of type 2 diabetes mellitusILTZ, Jason L; BAKER, Danial E; SETTER, Stephen M et al.Clinical therapeutics. 2006, Vol 28, Num 5, pp 652-665, issn 0149-2918, 14 p.Article

Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4)HILES, Richard A; BAWDON, Roger E; PETRELLA, Ezio M et al.Human & experimental toxicology. 2003, Vol 22, Num 12, pp 623-628, issn 0960-3271, 6 p.Article

Related expressional change of HIF-1α to the neuroprotective activity of exendin-4 in transient global ischemiaJIZI JIN; KANG, Hye-Min; JUNYANG JUNG et al.Neuroreport (Oxford). 2014, Vol 25, Num 1, pp 65-70, issn 0959-4965, 6 p.Article

Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivoXUEMIN ZHENG; YING LI; GANG FU et al.Peptides (New York, NY. 1980). 2011, Vol 32, Num 5, pp 964-970, issn 0196-9781, 7 p.Article

GLP-1 Receptor Agonists: Effects on Cardiovascular Risk ReductionLORBER, Daniel.Cardiovascular therapeutics (Print). 2013, Vol 31, Num 4, pp 238-249, issn 1755-5914, 12 p.Article

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metforminRIDDLE, Matthew C; HENRY, Robert R; POON, Terri H et al.Diabetes/metabolism research and reviews (Print). 2006, Vol 22, Num 6, pp 483-491, issn 1520-7552, 9 p.Article

Exenatide in type 2 diabetes : treatment effects in clinical studies and animal study dataGALLWITZ, B.International journal of clinical practice (Esher). 2006, Vol 60, Num 12, pp 1654-1661, issn 1368-5031, 8 p.Article

Exendin-4 decreases amphetamine-induced locomotor activityERREGER, Kevin; DAVIS, Adeola R; POE, Amanda M et al.Physiology & behavior. 2012, Vol 106, Num 4, pp 574-578, issn 0031-9384, 5 p.Article

Incretin mimetics as emerging treatments for type 2 diabetesJOY, Scott V; RODGERS, Philip T; SCATES, Ann C et al.The Annals of pharmacotherapy. 2005, Vol 39, Num 1, pp 110-118, issn 1060-0280, 9 p.Article

Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4KANOSKI, Scott E; FORTIN, Samantha M; ARNOLD, Myrtha et al.Endocrinology (Philadelphia). 2011, Vol 152, Num 8, pp 3103-3112, issn 0013-7227, 10 p.Article

GLP-1(7-36)-amide and Exendin-4 Stimulate the HPA Axis in Rodents and HumansGIL-LOZANO, Manuel; PEREZ-TILVE, Diego; ALVAREZ-CRESPO, Mayte et al.Endocrinology (Philadelphia). 2010, Vol 151, Num 6, pp 2629-2640, issn 0013-7227, 12 p.Article

Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosisMARZIONI, M; ALPINI, G; SACCOMANNO, S et al.Gut. 2009, Vol 58, Num 7, pp 990-997, issn 0017-5749, 8 p.Article

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaKENDALL, David M; RIDDLE, Matthew C; ROSENSTOCK, Julio et al.Diabetes care. 2005, Vol 28, Num 5, pp 1083-1091, issn 0149-5992, 9 p.Article

Incretin hormones and the satiation signalHOLST, J. J.International journal of obesity. 2013, Vol 37, Num 9, pp 1161-1168, issn 0307-0565, 8 p.Article

Exenatide : Its position in the treatment of type 2 diabetesGUERCI, B; SALAUN MARTIN, C.Annales d'endocrinologie. 2008, Vol 69, Num 3, pp 201-209, issn 0003-4266, 9 p.Article

Dérivés du GLP-1 et inhibiteurs de la DPP-IV : perspectives dans le traitement du diabète de type 2 = GLP-1 derivatives and dipeptidyl peptidase IV inhibitor in the treatment of type 2 diabetesBLICKLE, Jean-Frédéric.STV. Sang thrombose vaisseaux. 2006, Vol 18, Num 5, pp 265-269, issn 0999-7385, 5 p.Article

The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodentsEGECIOGLU, Emil; STEENSLAND, Pia; FREDRIKSSON, Ida et al.Psychoneuroendocrinology. 2013, Vol 38, Num 8, pp 1259-1270, issn 0306-4530, 12 p.Article

Noninsulin Treatment of Type 2 Diabetes Mellitus in Geriatric Patients: A ReviewGERMINO, F. Wilford.Clinical therapeutics. 2011, Vol 33, Num 12, pp 1868-1882, issn 0149-2918, 15 p.Article

A Randomized, Open-Label, Multicenter, 4-Week Study to Evaluate the Tolerability and Pharmacokinetics of ITCA 650 in Patients With Type 2 DiabetesHENRY, Robert R; LOGAN, Douglas; ALESSI, Thomas et al.Clinical therapeutics. 2013, Vol 35, Num 5, pp 634-645, issn 0149-2918, 12 p.Article